Exploratory study on determinant of pharmacokinetics of monoclonal antibodies in patients with advanced gastric cancer

Exploratory study on determinant of pharmacokinetics of monoclonal antibodies in patients with advanced gastric cancer - Exploratory study on determinant of pharmacokinetics of mAbs in patients with advanced gastric cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048208

Enrollment

Registered

2022-07-01

Start date

2017-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed gastric or gastroesophageal junction adenocarcinoma 2. Planned to receive therapy by trastuzuma or ramucirumab 3. Signed informed consent

Exclusion criteria

Exclusion criteria: Having the other status that investigators deem inappropriate

Design outcomes

Primary

Measure	Time frame
Association of exposure of mAbs	—

Countries

Japan

Contacts

Public ContactTakeshi Suzuki

Keio University, school of Medicine Division of Gastroenterology and Hepatology

takeshisuzuki1985@gmail.com03-3353-1211

Outcome results